{"filings":[{"id":535561,"accession_number":"0001711279-26-000047","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-05-20T00:08:52+00:00","items":["5.07"],"status":"ready","headline":"Krystal Biotech shareholders approve all four proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Krish S. Krishnan and Christopher Mason as Class III directors with ~89% and ~84% of votes cast.","Ratified KPMG as independent auditor for FY2026 with over 99.9% of votes in favor.","Advisory vote on named executive officer compensation passed with ~95.5% of votes cast.","Approved non-employee director compensation policy with ~90% of unaffiliated votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94902,"accession_number":"0001711279-26-000044","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q1 2026 revenue $116.4M (+32% YoY); net income $55.9M; pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK global revenue $116.4M, up 32% YoY from $88.2M; gross margin 95%.","Net income $55.9M ($1.83 diluted EPS) vs $35.7M ($1.20) in Q1 2025; cash $1.0B.","FDA granted platform technology designation for KB407 (CF) and KB111 (HHD) program vectors.","KB803 (DEB corneal abrasions) fully enrolled; top-line data expected 4Q 2026. KB801 (NK) data before year end.","FY 2026 non-GAAP R&D+SG&A guidance $175-195M; KB407 open-label study starting, KB111 HALITE-1 initiating."],"consensus_eps_estimate":null,"consensus_eps_actual":1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":116357000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107602,"accession_number":"0001711279-26-000018","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q4 2025 product revenue $107.1M; net income $51.4M; regulatory wins for KB707, KB111","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $107.1M (up from $91.1M YoY); FY revenue $389.1M; net income $204.8M ($7.08 basic EPS) vs $89.2M prior year.","FDA granted RMAT designation to KB707 for advanced NSCLC and Fast Track to KB111 for Hailey-Hailey disease.","Positive CORAL-1 CF data: inhaled KB407 achieved 29.4%-42.1% airway cell transduction; CORAL-3 enrollment expected 1H 2026.","Cash and investments $955.9M; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.","VYJUVEK has over 660 US reimbursement approvals; launched in Germany, France, Japan; Israel agreement signed."],"consensus_eps_estimate":null,"consensus_eps_actual":6.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":389130000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107601,"accession_number":"0001711279-26-000008","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Krystal Biotech pre-announces 2025 VYJUVEK revenue ~$388-389M; outlines 4 product launches by 2030","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 VYJUVEK net revenue $106-107M; full year $388-389M.","Cash, equivalents and investments ~$955M as of Dec 31, 2025.","Targets 4 marketed rare-disease medicines (incl. VYJUVEK) by end of 2030, treating >10,000 patients.","2026 combined non-GAAP R&D and SG&A expense guidance $175-195M (excl. stock comp).","Pipeline milestones: Phase 3 data for KB803 (ocular DEB) and KB801 (NK) in 2026; KB407 CF study enrollment starts."],"consensus_eps_estimate":null,"consensus_eps_actual":6.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":389130000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107600,"accession_number":"0001711279-26-000005","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech KB407 Phase 1 positive: CFTR delivery confirmed in all 6 biopsied patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations (modulator ineligible).","Transduction rates ranged 29.4% to 42.1% across six patients; all biopsies positive for CFTR or viral marker.","KB407 well tolerated; one SAE (asthma exacerbation) deemed procedure-related, resolved in 5 days.","Registrational CORAL-3 study design submitted to FDA; enrollment expected 1H 2026 after alignment.","Four of seven highest-dose patients were modulator ineligible; data supports mutation-agnostic potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123965,"accession_number":"0001711279-25-000092","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Krystal Biotech director Kirti Ganorkar resigns effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kirti Ganorkar resigned from Krystal Biotech Board on Dec 22, 2025 due to time constraints from promotion to Managing Director at Sun Pharma.","Resignation not due to disagreement with Board or management; effective Dec 31, 2025.","Ganorkar served on Board since company's IPO in September 2017.","Board thanks him for contributions; no successor identified in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123964,"accession_number":"0001711279-25-000088","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q3 VYJUVEK revenue $97.8M; label expanded, EU/Japan launches","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product revenue $97.8M (vs $83.8M YoY); net income $79.4M ($2.74 basic EPS); cash $864.2M.","FDA expanded VYJUVEK label to include DEB patients from birth and allow at-home application.","VYJUVEK launched in Germany (Aug), France (Oct), and Japan (Oct); >615 US reimbursement approvals.","FDA granted platform technology designation to HSV-1 vector used in KB801 and other programs.","CF interim data (KB407) expected Q4; KB111 IND cleared for Hailey-Hailey disease; intratumoral KB707 enrollment paused."],"consensus_eps_estimate":null,"consensus_eps_actual":5.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":282025000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123963,"accession_number":"0001711279-25-000082","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Krystal Biotech launches VYJUVEK in Japan at NHI price of 2.955M yen per unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subsidiary Krystal Biotech Japan KK commenced commercial launch of VYJUVEK (beremagene geperpavec) on Oct 22, 2025.","VYJUVEK added to Japan's National Health Insurance Drug Price List at 2,955,232.7 yen per unit.","Drug indicated for dystrophic epidermolysis bullosa, a rare genetic skin disorder.","Launch follows NHI listing, enabling patient access with government reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140636,"accession_number":"0001711279-25-000078","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q2 2025 net income $38.3M ($1.29 diluted EPS) on $96M VYJUVEK revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK net product revenue $96.0M in Q2 2025, up from $70.3M in Q2 2024; gross margin 93%.","Net income $38.3M vs $15.6M YoY; basic EPS $1.33, diluted EPS $1.29.","Cash and investments $820.8M; FY 2025 non-GAAP R&D+SG&A guidance $150-175M.","VYJUVEK approved in Japan for DEB patients from birth; launch expected by end of 2025.","First patient dosed in Phase 3 IOLITE study (KB803 for corneal abrasions in DEB) and Phase 2 EMERALD-1 (KB801 for NK)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":184225000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140635,"accession_number":"0001711279-25-000071","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech's VYJUVEK approved in Japan for dystrophic epidermolysis bullosa","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Japan's MHLW granted marketing authorization for VYJUVEK on July 24, 2025 for DEB from birth.","First genetic medicine approved in Japan for DEB; allows home dosing and administration by patients or family.","Based on Phase 3 data and Japanese open-label extension; all 4 patients achieved full wound closure at 6 months.","Re-examination period is 10 years; launch expected in Japan by end of 2025.","Previously approved in US (May 2023) and EU (April 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140634,"accession_number":"0001711279-25-000069","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech subsidiary Jeune reports 100% investigator-rated GAIS improvement in Phase 1 KB304 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PEARL-2 Phase 1 trial: 100% of KB304-treated subjects achieved ≥1-point investigator GAIS improvement at 1,2,3 months vs 14-29% for placebo.","81.8% of KB304 subjects reported improved satisfaction on SSQ at 3 months vs 14.3% for placebo; improvements also seen in elasticity, crepiness, hydration, radiance.","Safety consistent with prior KB301 experience: no severe or drug-related serious AEs; AEs mild-to-moderate and decreased with subsequent doses.","Company plans to meet with FDA in H2 2025 to align on Phase 2 protocol; target Phase 2 start in H1 2026 for décolleté wrinkles.","KB304 is first candidate to combine collagen (COL3) and elastin delivery via gene therapy to restore skin naturally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140633,"accession_number":"0001711279-25-000065","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech doses first patient in Phase 1/2 trial of KB801 for neurotrophic keratitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1/2 EMERALD-1 trial of KB801, a redosable eye-drop gene therapy for neurotrophic keratitis.","Study enrolls up to 27 adults with Stage 2 or 3 NK; 2:1 randomized to KB801 or placebo twice weekly for 8 weeks.","Primary endpoint: safety/tolerability; secondary: complete durable corneal healing at week 8.","NK diagnosed claims in US rose 115% from ~31,000 (2020) to ~68,000 (2024), per claims data.","Investor call/webcast July 9 at 8:30am ET to discuss KB801 program and trial design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158346,"accession_number":"0001711279-25-000055","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inhaled KB707 monotherapy achieves 27% ORR in advanced NSCLC; updated to 36%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["27% ORR (3/11 PR) in heavily pre-treated NSCLC; extended follow-up yields 36% (4/11 PR).","Median DOR and PFS not reached; responses durable.","Safety well-tolerated: most TRAEs Grade 1/2, no Grade 4/5; MTD not reached.","Combination cohort with pembrolizumab enrolling for NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158345,"accession_number":"0001711279-25-000051","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Krystal Biotech stockholders elect Class II directors, ratify KPMG, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Daniel S. Janney, Dino A. Rossi, and E. Rand Sutherland as Class II directors for three-year terms.","Janney received 19,838,511 votes for; Rossi 23,336,879; Sutherland 23,337,104; broker non-votes 3,770,846.","Ratification of KPMG as independent auditor for FY2025: 27,723,997 for, 14,761 against, 5,354 abstentions.","Advisory vote on named executive officer compensation approved: 22,543,683 for, 1,423,437 against, 6,146 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158344,"accession_number":"0001711279-25-000048","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Krystal Biotech presents preclinical data for KB111 (HHD) and KB112 (Darier) at SID 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KB111 targets ATP2C1 for Hailey-Hailey disease; KB112 targets ATP2A2 for Darier disease.","Both HSV-1-based vectors transduced keratinocytes with dose-dependent target protein expression and no cytotoxicity.","KB111 functionally corrected ATP2C1 siRNA knockdown in keratinocytes, reversing F-actin loss (p<0.05).","Topical administration in mice showed proper localization of ATP2C1 and ATP2A2 with minimal toxicity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158343,"accession_number":"0001711279-25-000045","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q1 VYJUVEK revenue $88.2M; net income $35.7M; EU approval secured","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK net product revenue $88.2M in Q1 2025 (vs $45.3M Q1 2024); gross margin 94%.","Net income $35.7M ($1.24 basic EPS) vs $0.9M ($0.03) year ago; cash $765.3M.","European Commission approved VYJUVEK for DEB; first Germany launch mid-2025; Japan decision expected 2H2025.","Second ophthalmic program KB801 IND cleared for neurotrophic keratitis; Phase 1/2 EMERALD-1 starts May 2025.","FY2025 non-GAAP R&D+SG&A guidance $150-175M; upcoming readouts for CF, AATD, ocular DEB, aesthetics."],"consensus_eps_estimate":null,"consensus_eps_actual":1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":88183000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158342,"accession_number":"0001711279-25-000037","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech Presents Preclinical Data on KB801 Gene Therapy for Neurotrophic Keratitis at ARVO 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KB801 is a topical HSV-1-based vector encoding human NGF for neurotrophic keratitis, disclosed in an 8-K filed May 5, 2025.","In vitro, KB801 transduction of primary human corneal epithelial cells resulted in dose-dependent secretion of mature, functional NGF protein.","In a murine corneal wound model, a single topical KB801 dose produced higher peak NGF (491 pg/eye) and prolonged exposure (t1/2 55.5 hrs) vs. rhNGF (t1/2 83 min).","After eight weekly topical KB801 doses, eyes showed only mild inflammatory infiltrate with no necrosis; all resolved by 27 days post-treatment.","Poster presented at ARVO 2025 Annual Meeting in Salt Lake City, Utah on May 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158341,"accession_number":"0001711279-25-000029","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech announces EC approval of VYJUVEK for DEB; launch in Germany mid-2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EC granted marketing authorization for VYJUVEK (beremagene geperpavec-svdt) to treat DEB from birth.","Flexible dosing: at home or healthcare setting; patient/caregiver administration if appropriate.","First corrective medicine for DEB in Europe; launch in Germany mid-2025; 1,000 DEB patients identified in France and Germany."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176729,"accession_number":"0001711279-25-000013","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech receives positive CHMP opinion for VYJUVEK in EU; EC decision expected Q2 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP recommends EC approval of VYJUVEK for DEB wounds, including from birth, with option for at-home administration.","Final EC decision anticipated in Q2 2025, applicable to EU member states plus Iceland, Norway, Liechtenstein.","Positive opinion based on Phase 1/2 GEM-1 and Phase 3 GEM-3 data showing durable wound closure.","Company expects first European launch in Germany around mid-2025, followed by France later in 2025.","VYJUVEK previously approved by FDA in May 2023 for DEB patients aged 6 months and older in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176728,"accession_number":"0001711279-25-000009","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q4 revenue $91.1M (+116% YoY); net income $45.5M; FY revenue $290.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 product revenue $91.1M (+116% YoY); full year $290.5M (+473% vs 2023).","Q4 2024 net income $45.5M ($1.58 basic EPS) vs $8.7M ($0.31) in Q4 2023.","Cash, cash eq & investments $749.6M as of Dec 31, 2024.","Pipeline: KB707 solid tumors ORR 27%; KB408 AATD interim positive; CFF sanctioned KB407 CF study.","FY2025 non-GAAP R&D+SG&A guidance $150-175M."],"consensus_eps_estimate":null,"consensus_eps_actual":3.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":290515000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193546,"accession_number":"0001711279-24-000065","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech reports 27% ORR and 73% DCR for inhaled KB707 in advanced NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 27% (3 partial responses) and DCR of 73% in 11 evaluable NSCLC patients as of Dec 6, 2024.","Lung target lesion ORR 36% (3 partial, 1 complete response) and DCR 82%.","Treatment-emergent AEs mild to moderate; no Grade 4/5 events; outpatient administration feasible.","Protocol amended to add two combination cohorts (with anti-PD-1 ± chemo) for advanced NSCLC.","Enrollment ongoing; detailed results to be presented at future scientific meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193545,"accession_number":"0001711279-24-000062","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech reports positive initial clinical data for inhaled gene therapies KB408 (AATD) and KB407 (CF)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KB408: single dose increased lung AAT from 85nM to 729nM in AATD patient; active neutrophil elastase dropped >50%.","Gene delivery confirmed: 39% of airway cells AAT-positive post-dose vs 0% at baseline.","KB407 for CF: Phase 1 CORAL-1 granted conditional sanctioning by CFF TDN; safe and well tolerated.","KB407 enrolling Cohort 3 (4 daily doses); data expected 1H 2025.","No serious adverse events in either program; all adverse events mild to moderate and transient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193544,"accession_number":"0001711279-24-000055","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q3 net product rev $83.8M; VYJUVEK approvals reach 460; JNDA filed in Japan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $83.8M from VYJUVEK; $250.1M total since Aug 2023 launch.","Net income $27.2M ($0.91 diluted) vs $80.7M ($2.79) in Q3 2023; SG&A rose to $28.7M.","Cash and investments $694.2M; 460+ U.S. reimbursement approvals secured as of October.","JNDA filed for B-VEC in Japan; EMA decision expected before year end; French early access approved.","Guidance: non-GAAP R&D+SG&A $115-125M for FY2024; key pipeline data due by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":199376000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209855,"accession_number":"0001711279-24-000045","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jeune Aesthetics reports positive Phase 1 interim results for KB301 in wrinkles; plans Phase 2 for décolleté","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["94% of décolleté subjects had ≥1-point improvement on GAIS at two months; 89% reported improved wrinkle satisfaction.","75% of lateral canthal subjects had ≥1-point improvement on GAIS at two months; 67% reported improved satisfaction.","No drug-related serious adverse events; adverse events were mild-to-moderate and transient.","Phase 2 study for dynamic wrinkles of the décolleté expected to start next year; FDA meeting planned.","Improvements also seen in crepiness, hydration, and radiance in both cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209854,"accession_number":"0001711279-24-000038","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q2 revenue $70.3M; net income $15.6M; three pipeline readouts on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK net product revenue $70.3M in Q2 2024, up 55.3% vs Q1 2024.","Net income $15.6M ($0.53 diluted EPS) vs net loss ($33.2M) in Q2 2023.","Cash and investments $628.9M at June 30, 2024; strong balance sheet.","On track for three clinical data readouts in 2H 2024: KB301 (3Q), KB408 (4Q), KB707 (4Q).","Received Rare Pediatric Disease Designation for intratumoral KB707 for osteosarcoma in May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":115535000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228053,"accession_number":"0001711279-24-000027","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Krystal Biotech stockholders elect directors, ratify auditor, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors Suma M. Krishnan, Julian S. Gangolli, and Catherine Mazzacco elected with 21.1M, 17.2M, and 20.4M votes for, respectively.","Ratification of KPMG as independent auditor for FY2024: 24.8M for, 7.4K against, 22.8K abstentions.","Advisory approval of named executive officer compensation for FY2023: 21.7M for, 851.7K against, 7.0K abstentions.","Broker non-votes of 2.2M for director election and say-on-pay; no broker non-votes on auditor ratification.","All proposals passed with strong majority support; no material changes to board or governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228052,"accession_number":"0001711279-24-000023","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech presents preclinical ocular gene therapy data at ARVO 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Subretinal and suprachoroidal injections achieved widespread mCherry expression across the retina in mice.","Vector transduced both photoreceptors (RHO+) and RPE cells (RPE65+) with minimal inflammation.","Intravitreal injection resulted in mCherry signal in cornea, iris, and ciliary body, not retina.","Low systemic dissemination detected; platform shows potential for inherited retinal diseases (IRDs)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228051,"accession_number":"0001711279-24-000018","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q1 2024 net income $0.9M; VYJUVEK revenue $45.3M; cash $622M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $0.9M ($0.03 EPS) vs net loss $45.3M ($1.76 loss) in Q1 2023.","VYJUVEK net product revenue $45.3M, gross margin 95%, patient compliance 91%.","Cash $622.3M; FY 2024 Non-GAAP R&D+SG&A guidance $150M-$175M.","Pipeline: KB408 AATD first patient; KB407 CF Cohort 2 complete; inhaled KB707 first patient; intratumoral KB707 Cohort 3 enrolled.","Regulatory: European MAA decision and GMP certification expected 2H 2024; Japan NDA filing target 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":45250000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}